

1
2
3
4
5
6
7

**PROTOCOL FOR THE DERIVATION OF ENVIRONMENTAL QUALITY
GUIDELINES FOR THE PROTECTION OF APEX MARINE MAMMALS
FROM BIOACCUMULATIVE SUBSTANCES**

DRAFT FOR REVIEW ONLY – DO NOT CITE OR COPY

8 **NOTE TO READER**

9
10 The Canadian Council of Ministers of the Environment (CCME) is the primary minister-led
11 intergovernmental forum for collective action on environmental issues of national and
12 international concern.

13 This document was developed by the Marine Mammal Protocol Sub-Committee of the Southern
14 Resident Killer Whale Contaminants Technical Working Group. Funding was provided by
15 Environment and Climate Change Canada (ECCC), Fisheries and Oceans Canada, and the British
16 Columbia Ministry of Environment and Parks.

17
18 CCME would like to thank the various peer reviewers for their valuable comments, including
19 Marie-Odile Fouchécourt for providing insight on human health risk assessment.

20
21 Sections 5, 6 and 7 of this document in their entirety are reproduced from “A framework for the
22 derivation of environmental quality guidelines that protect apex marine mammals from persistent
23 organic pollutants (POPs)” (McTavish *et al.* 2024) with minor changes.

24
25 Ce document est aussi disponible en français.

26
27

28 **NOTICE**

29
30 This document is intended for general guidance only and does not establish or affect legal rights
31 or obligations. It does not establish a binding norm, or prohibit alternatives not included in the
32 document and is not finally determinative of the issues addressed. Decisions in any particular case
33 will be made by applying the law and regulations on the basis of specific facts when regulations
34 are promulgated or permits are issued.

35 **TABLE OF CONTENTS**

36 **NOTE TO READER**..... i

37 **NOTICE** i

38 **LIST OF TABLES** iii

39 **LIST OF FIGURES** iii

40 **GLOSSARY**..... 1

41 **LIST OF ACRONYMS**..... 3

42 **1. INTRODUCTION**..... 1

43 1.1 Background..... 2

44 1.2 Guiding Principles 3

45 **2. SELECTION OF SUBSTANCES FOR GUIDELINE DEVELOPMENT** 3

46 2.1 Mixture Considerations..... 4

47 2.2 Minimum Data Requirements..... 4

48 **3. CONSIDERATIONS FOR USE** 4

49 3.1 Guideline Exceedances 4

50 3.2 Deciding Which Guideline to Apply 5

51 3.3 Site-Specific Guidelines or Objectives 5

52 3.4 Environment Quality Guidelines Below Ambient Concentrations..... 6

53 **4. COMPILATION OF BACKGROUND INFORMATION**..... 6

54 4.1 Literature Search..... 6

55 4.2 Environmental Concentrations..... 7

56 4.3 Analytical Methods..... 7

57 4.4 Bioaccumulation Factors 7

58 4.5 Mode of Toxic Action..... 8

59 **5. DERIVATION OF A TOXICITY REFERENCE VALUE FOR MARINE**

60 **MAMMALS**..... 8

61 5.1 What Is a Toxicity Reference Value and How Is It Derived? 8

62 5.2 Selection of a Point of Departure..... 9

63 5.3 Selection of Uncertainty Factors..... 10

64 5.4 Calculation of the Marine Mammal Toxicity Reference Value..... 11

65 5.5 Consideration of Carcinogenic Effects 11

66	6. ESTIMATING CONCENTRATIONS IN OTHER ENVIRONMENTAL MEDIA	12
67	
68	6.1. Overview.....	12
69	6.2. Biomagnification Factor—Marine Mammal to Prey.....	13
70	6.3. Bioaccumulation Factor—Prey to Water.....	16
71	6.4. Estimating Sediment Concentrations.....	17
72	6.5. Criteria for Other Models.....	18
73	7. CALCULATION OF THE FINAL CANADIAN ENVIRONMENTAL QUALITY	
74	GUIDELINES.....	19
75	7.1. Dietary Guideline.....	19
76	7.2. Water Quality Guideline.....	20
77	7.3. Sediment Quality Guideline.....	20
78	7.4. Weight-of-Evidence Review.....	21
79	REFERENCES.....	22
80	APPENDICES.....	27
81	Appendix A: Compilation and Evaluation of Toxicity Data.....	27
82	Appendix B: Individual-based Model Input Values and Rate of Food Intake to Body Weight	
83	Estimates.....	30
84		
85		
86	LIST OF TABLES	
87	Table 1. Mean Calf or Pup Biomagnification Factors (Wet-Weight-Based) for a Range of K_{ow}	
88	Values.....	15
89		
90		
91	LIST OF FIGURES	
92	Figure 1. General Steps for the Derivation of Canadian Environmental Quality Guidelines for the	
93	Protection of Apex Marine Mammals from Organic Contaminants That Are Persistent,	
94	Bioaccumulative and Toxic.....	2
95	Figure 2. Pathways for the Derivation of Environmental Quality Guidelines for Prey Tissue, Water	
96	and Sediment Starting with a Surrogate Toxicity Reference Value.....	13
97		

98 **GLOSSARY**

99

100 **Apex marine mammal:** Marine mammal species and species functional group at the top of the
101 food chain (food web) with no natural predators in its environment.

102

103 **Bioaccumulation:** Process by which aquatic organisms accumulate chemical substances directly
104 from water or through the consumption of food containing the chemicals (Canadian Council of
105 Resource and Environment Ministers [CCREM] 1987).

106

107 **Bioconcentration:** Process by which there is a net accumulation of a chemical directly from water
108 within aquatic organisms resulting from simultaneous uptake (e.g., by gill or epithelial tissue) and
109 elimination (CCREM 1987).

110

111 **Biomagnification:** Result of the processes of bioconcentration and bioaccumulation by which
112 tissue concentrations of bioaccumulated chemicals increase as the chemical passes up through two
113 or more trophic levels. The term implies an efficient transfer of chemicals from food to consumer
114 so that residue concentrations increase systematically from one trophic level to the next (CCREM
115 1987).

116

117 **Biomarker:** Physiological, histological or biochemical measurement indicating that an organism
118 has experienced stress from contaminant exposure.

119

120 **Biomonitoring:** Monitoring biological components of ecosystems (e.g., biomarkers, species
121 presence or absence, diversity) to estimate organismic or ecosystem stress.

122

123 **Environmental Quality Guideline (EQG):** Scientifically derived numerical concentration or
124 narrative statement describing what is considered to be protective of designated values in ambient
125 conditions.

126

127 **K_{oc}:** Organic carbon-water partition coefficient. It is a parameter that is used to express the extent
128 to which an organic chemical partitions itself between the soil or sediment and solution phases.

129

130 **K_{ow}:** Octanol/water partition coefficient. The ratio of a chemical's solubility in n-octanol and
131 water at equilibrium. The logarithm of K_{ow} is used as an indication of a chemical's propensity for
132 bioconcentration by aquatic organisms (CCREM 1987).

133

134 **Mode of action (MOA):** Cellular or molecular mechanisms through which a toxic substance
135 exerts its harmful effects on an organism.

136

137 **Point of departure (POD):** Point in a toxicological dose-response data set generally
138 corresponding to an estimated low effect level or no effect level (e.g., benchmark dose lower
139 confidence limit [BMDL], effect concentration affecting 10% of the test organisms [EC10], no
140 observed adverse effect level [NOAEL], lowest observed adverse effect level [LOAEL]).

141

142 **Tissue residue:** Chemical substance in aquatic biota tissue, such as fish, shellfish, invertebrates
143 and aquatic plants, on a whole-body, wet-weight basis.

144 **Toxicity reference value (TRV):** Parameter used to quantitatively assess potential risks to human
145 health or the environment that are associated with exposure to a chemical or contaminant of
146 concern.

147
148 **Trophic magnification factor (TMF):** Diet-weighted average biomagnification factor (BMF) of
149 chemical residues across food webs.

150
151 **Weight of evidence (WoE):** Method for decision-making that involves the consideration of
152 multiple sources of information and lines of evidence.

DRAFT FOR REVIEW ONLY – DO NOT CITE OR COPY

153 LIST OF ACRONYMS

154		
155	ADME	absorption, distribution, metabolism and excretion
156	AOP	adverse outcome pathway
157	ATSDR	Agency for Toxic Substances and Disease Registry
158	BAF	bioaccumulation factor
159	BC ENV	British Columbia Ministry of Environment and Climate Change Strategy
160	BMD	benchmark dose
161	BMDL	benchmark dose lower confidence limit
162	BMF	biomagnification factor
163	BSAF	biota-sediment accumulation factor
164	bw	body weight
165	CCME	Canadian Council of Ministers of the Environment
166	CCREM	Canadian Council of Resource and Environment Ministers
167	CDG _{mm}	Canadian dietary guideline for the tissue of marine mammal prey
168	CEQG	Canadian Environmental Quality Guideline
169	CEQG _{mm}	Canadian Environmental Quality Guideline for the protection of marine mammals
170	CSeQG _{mm}	Canadian Sediment Quality Guideline for the protection of marine mammals
171	CWQG _{mm}	Canadian Water Quality Guideline for the protection of marine mammals
172	DFO	Fisheries and Oceans Canada
173	DG _{mm}	dietary guideline for the protection of marine mammals
174	ECCC	Environment and Climate Change Canada
175	EC _x	effect concentration causing response in x% of test organisms
176	EQG _{mm}	environmental quality guideline for the protection of marine mammals
177	FI:BW	rate of food intake to body weight
178	IBM	individual-based model
179	KC	key characteristic
180	K _{oc}	organic carbon-water partition coefficient
181	K _{ow}	octanol-water partition coefficient
182	LOAEL	lowest observable adverse effect level
183	MATC	maximum acceptable toxicant concentration
184	MDL	method detection limit
185	MoA	mode of action

186	MoD	method of detection
187	NOAEL	no observable adverse effect level
188	OC	organic carbon
189	PAH	polycyclic aromatic hydrocarbon
190	PBDE	polybrominated diphenyl ether
191	PBT	persistent, bioaccumulative and toxic
192	PCB	polychlorinated biphenyl
193	PFAS	per- and polyfluoroalkyl substances
194	POD	point of departure
195	POP	persistent organic pollutant
196	QSAR	quantitative structure-activity relationship
197	SeQG _{mm}	sediment quality guideline for the protection of marine mammals
198	SLEB	St. Lawrence Estuary beluga
199	SRKW	Southern resident killer whale
200	TMF	trophic magnification factor
201	TOC	total organic carbon
202	TRV	toxicity reference value
203	UF	uncertainty factor
204	US EPA	United States Environmental Protection Agency
205	WoE	weight of evidence
206	WQG _{mm}	water quality guideline for the protection of marine mammals

DRAFT FOR REVIEW ONLY – DO NOT CITE OR COPY

1. INTRODUCTION

This document outlines the procedures for deriving consistent and scientifically defensible Canadian Environmental Quality Guidelines (CEQGs) for the protection of apex marine mammals against organic contaminants deemed to be persistent, bioaccumulative and toxic (PBTs). An apex predator is a species at the top of the food chain with no natural predators in their environment. PBT contaminants are those that are resistant to degradation from biotic or abiotic factors, accumulate in biota over time and increase with each trophic level in aquatic food webs. In some marine mammals, concentrations of these contaminants can reach levels that can elicit harm to endocrine, immune and reproductive systems (Desforges *et al.* 2016; Fair and Houde 2023; Mos *et al.* 2010; Ross *et al.* 1996). Contaminants are considered a primary anthropogenic threat to several marine mammal species and populations, including the endangered St. Lawrence Estuary beluga (SLEB, *Delphinapterus leucas*), the Southern resident killer whale (SRKW, *Orcinus orca*), also called the orca whale, and many other species listed under the *Species at Risk Act* (SARA) (Committee on the Status of Endangered Wildlife in Canada [COSEWIC] 2018; Department of Fisheries and Oceans [DFO] 2018).


Apex marine mammals are typically long-lived and are not able to metabolize, bio-transform or excrete persistent contaminants to reduce their body burden. This results in the accumulation of contaminants over many years and over many generations, increasing the risk of elevated chemical burdens (Alava and Gobas 2012). Apex marine mammals have high lipid tissue content (e.g., blubber) in their bodies and rely on fat storage for energy in various situations (e.g., during times of low prey availability or nutritional stress; Banfield 1974). Most organic contaminants are lipid-soluble and therefore stored in the blubber (Mos *et al.* 2010; Ross *et al.* 1996). Females transfer significant quantities of persistent contaminants to their offspring *in utero* via the placenta or through lactation (i.e., maternal transfer) (Barrett *et al.* 2021; Desforges *et al.* 2012; Lee *et al.* 2023). In addition to chemical contamination, marine mammals are often sensitive and vulnerable to other anthropogenic stressors that act cumulatively, including prey availability, vessel and physical disturbance and climate change (Alava *et al.* 2018).

In this document, a protocol is presented for the derivation of Canadian Environmental Quality Guidelines for the Protection of Apex Marine Mammals (CEQGs_{mm}) from bioaccumulative substances, herein referred to as “this protocol.” The approach outlined in this protocol was produced by the Marine Mammal Protocol Sub-Committee of the Southern Resident Killer Whale Contaminants Technical Working Group and published previously (McTavish *et al.* 2024). This approach is based on methodologies used in the Canadian Council of Ministers of the Environment (CCME) protocol for deriving wildlife tissue residue guidelines (CCME 1998) as well as human health risk assessment methodologies. In this protocol, available marine mammal data are combined with rodent data generated for human health assessments to support a weight-of-evidence (WoE) approach to guideline development. Ecological modelling is then used to calculate CEQGs_{mm} from PBT substances for three environmental compartments: marine mammal prey tissue, sediment and water. The general steps of guideline derivation are summarized in Figure 1 and are further explained through the rest of this document.

This document provides a method to derive CEQGs_{mm} from PBT substances by including more sensitive endpoints applicable to the protection of vulnerable individuals, instructions for use of

253 toxicity reference values (TRVs) derived for humans, biomagnification factors (BMFs) to account
254 for contaminant accumulation in apex marine mammals, and a modelling approach to calculate
255 guideline values in sediment and water as well as prey tissue.

256
257



258 **Figure 1. General Steps for the Derivation of Canadian Environmental Quality**
259 **Guidelines for the Protection of Apex Marine Mammals from Organic**
260 **Contaminants That Are Persistent, Bioaccumulative and Toxic**

261 **Notes:**
262 BAF = bioaccumulation factor; BMF = biomagnification factor; CEQG_{mm} = Canadian Environmental Quality Guideline for the protection
263 of marine mammals; PBT = persistent, bioaccumulative and toxic; TRV = toxicity reference value.

264
265

266 **1.1 Background**

267
268 CEQGs are developed by CCME using formal protocols to provide a consistent, scientifically
269 defensible approach for assessing and managing toxic substances in the environment. These
270 guidelines provide numerical concentrations or narrative statements describing the maximum
271 recommended concentrations that should be present in various media (i.e., water, sediment, tissue
272 and soil) to protect, enhance and restore designated environmental values and species. CEQGs
273 provide benchmarks to help interpret biological monitoring data and serve as the scientific basis

274 for determining interim management objectives and performance indicators to measure progress
275 in virtual elimination strategies. They do not have any direct legal standing unless prescribed by
276 regulation or binding agreements. An exceedance of a CEQG does not necessarily imply that
277 unacceptable risks are present, but that the potential for adverse effects is increased and additional
278 investigation and monitoring are warranted.

279
280

281 **1.2 Guiding Principles**

282

- 283 • Guidelines are generic (i.e., not species- or site-specific) Canada-wide recommendations
284 that are based on the most current scientific information available at the time of their
285 derivation. They do not directly consider site-specific, technological, socioeconomic or
286 management factors that may influence their implementation.
- 287 • Guidelines are meant to protect all apex marine mammals in Canada and all aspects of their
288 life stages or cycles, including the most sensitive life stage of the most sensitive species
289 indefinitely (i.e., chronic exposures or shorter-term exposure during periods of
290 development), from the negative effects of exposure to toxic substances. Therefore,
291 guideline derivation should focus on the most sensitive sub-population, which is often
292 neonates or nursing juveniles.
- 293 • CEQGs_{mm} are intended to protect individuals of the population, which in turn also protects
294 populations and communities. This is a necessary consideration for marine mammals that
295 are top predators and, in some cases, endangered (e.g., SRKW). This approach may not
296 protect individuals already weakened through age, illness, injury or cumulative stress from
297 climate change, declining prey availability and shipping-related disturbance.
- 298 • Guideline derivation assumes the main route of exposure to PBT substances for apex
299 marine mammals is the consumption of contaminated aquatic prey. Other routes of
300 exposure may be incorporated if deemed necessary.
- 301 • Guideline derivation should follow a WoE approach (see Section 5.4) that considers data
302 from all valid sources, including marine mammal biomarker data and laboratory animal
303 data, to support decisions.
- 304 • Guideline derivation must be done in a clear and transparent manner and, whenever
305 possible, follow the process outlined in this document.

306
307

308 **2. SELECTION OF SUBSTANCES FOR GUIDELINE DEVELOPMENT**

309

310 This protocol is specifically intended for organic substances that are persistent, bioaccumulative
311 and toxic. PBT chemicals typically have a bioconcentration factor (BCF) or bioaccumulation
312 factor (BAF) of $\geq 5,000$ or a log octanol-water partition coefficient (K_{ow}) of ≥ 5 and are persistent
313 in the environment (e.g., half-lives in water and sediment of ≥ 182 days and ≥ 365 days,
314 respectively) (Gobas *et al.* 2009; Government of Canada 2000). The definitions of “persistent” and
315 “bioaccumulative” adopted here align with those of the *Canadian Environmental Protection Act*
316 (Government of Canada 2000).

317 For derivation of CEQGs to proceed, there must be evidence that marine mammals are being
318 exposed to the substance or substance group. This will be confirmed via published, peer-reviewed

319 studies or government monitoring data that documents the substance's presence in marine mammal
320 tissue or its prey. In accordance with the precautionary principle, monitoring data that indicate the
321 environmental presence of the substance, its associated negative effects, and the likelihood of
322 continued or future exposure should all be considered when determining if guideline development
323 is necessary. This protocol may be used by multiple jurisdictions in Canada which may have
324 additional criteria for selecting priorities. Therefore, the selection of substances for guideline
325 development may vary across jurisdictions.

326
327 Given the complexity associated with developing CEQGs_{mm}, including those associated with
328 ecological modelling, this protocol is offered as a framework for guideline derivation. Elements
329 of this framework may not provide the best methodology for some substances. In these cases, the
330 guiding principles of this protocol must be followed, and an effort made to include as many of the
331 protocol's elements as possible in guideline derivation. Further, the process must be documented
332 in a clear and transparent manner.

333
334

335 **2.1 Mixture Considerations**

336
337 Many organic substances occur as groups of similar molecules, such as polychlorinated biphenyls
338 (PCBs), polybrominated diphenyl ethers (PBDEs), per- and polyfluoroalkyl substances (PFAS)
339 and polycyclic aromatic hydrocarbons (PAHs). When possible, guidelines should give options for
340 considering mixtures of chemicals including the use of toxicity equivalency factors, toxic units or
341 total concentrations for congeners within a given class.

342
343

344 **2.2 Minimum Data Requirements**

345
346 The following minimum data set must be present before proceeding with guideline derivation:

- 347 • at least one study documenting a marine mammal that has been exposed to the contaminant
- 348 • a human health TRV with the associated effect concentration OR at least three acceptable
349 dose-response toxicity studies (*in vivo*) from a mammalian species OR mammal-based
350 point of departure (POD) that is published by an agency and is scientifically credible.

351
352 Guideline developers should collect as many lines of evidence as possible to support a WoE
353 approach.

354 **3. CONSIDERATIONS FOR USE**

355 **3.1 Guideline Exceedances**

356
357 CEQGs are predicted no-effect concentrations, representing low-risk conditions, that have been
358 extrapolated from the existing ecotoxicological data sets according to the procedures herein.
359 Therefore, exceeding CEQG values does not necessarily mean adverse effects will occur but
360 suggests further investigation is warranted. Guideline exceedances can be defined in many ways.
361 For example, an exceedance could be based on a single sample, a 30-day average or a certain
362

363 magnitude or frequency rate. It is suggested to follow provincial or territorial jurisdictional
364 guidance for your site. Whenever possible, collect sufficient high-quality monitoring data and
365 define an exceedance prior to evaluating the monitoring data for exceedances. Interpretation
366 requires knowledge of the local environment, professional judgement and other lines of evidence
367 to ensure effective decision-making and resource management.
368

369

370 **3.2 Deciding Which Guideline to Apply**

371

372 **3.2.1 Different Receptors**

373

374 This protocol outlines the derivation process for CEQGs_{mm} from PBT substances. However, other
375 guidelines may already exist for these substances based on different protocols to protect various
376 aquatic receptors or terrestrial receptors who feed on aquatic biota (CCME 1995, 1998, 2007;
377 British Columbia Ministry of Environment and Climate Change Strategy [BC ENV] 2019). These
378 guidelines may be appropriate to use depending on the site and species present. For example,
379 CEQGs_{mm} are not appropriate where marine mammals are not present and where the substance is
380 not expected to affect downstream marine mammal habitat.
381

382

383

384 **3.2.2 Different Environmental Compartments**

385

386 The dietary CEQG, which is the tissue concentration in prey that is predicted to have no effect on
387 apex marine mammals, is the most reliable CEQG produced by this protocol given that tissue
388 concentrations in prey are representative of the average environmental concentrations and given
389 that tissue concentrations have lower uncertainty compared to the modeled water and sediment
390 CEQGs. However, as sampling is more commonly done on abiotic media, the water and sediment
391 CEQGs can be used to assess risks to marine mammals. Care must be taken, however, to ensure
392 that the sampling protocol considers spatial and temporal variations in contaminant concentrations.

393

394 It is recommended that all values available (i.e., tissue, sediment, water) be used in close
395 conjunction with each other if monitoring data allows. It is also recommended to use all available
396 metrics when assessing pollution risks and to use other decision-making tools in addition to
397 CEQGs.

398

399

400 **3.3 Site-Specific Guidelines or Objectives**

401

402 This protocol outlines how to derive generic guidelines intended to protect all marine mammals in
403 Canada. However, a site-specific guideline may be appropriate provided that accurate site- and
404 species-specific information is available. For example, the food-web bioaccumulation models can
405 be tailored to the specific site and species of interest by including model inputs specific to that
406 habitat or ecosystem (for examples, see Alava *et al.*, 2012). In addition, food intake and body
407 weight information can be used from the species or population of interest rather than using a default
408 value. A site-specific or habitat-specific guideline can be developed when no generic guideline
exists for that substance by following the same general procedures outlined in this document or

409 adapted from an existing generic guideline already developed. Guidelines can also help inform
410 site-specific objectives which, in contrast to guidelines, may consider technological,
411 socioeconomic, or management factors for specific water bodies (BC ENV 2021; CCME 2003;
412 Rao *et al.*, 2019).

413
414

3.4 Environment Quality Guidelines Below Ambient Concentrations

415
416

In some cases, the CEQG may be below the ambient concentrations of a contaminant. This reflects
417 both the historical use of some contaminants and the persistence of these contaminants. It also
418 indicates that current ambient concentrations may be causing adverse health impacts to marine
419 mammals. Efforts should therefore be made to reduce the loading of additional contaminants to
420 marine mammal habitats.

421
422
423

4. COMPILATION OF BACKGROUND INFORMATION

424
425

4.1 Literature Search

426
427

Comprehensive data on the toxicology of a substance are necessary for the development of
428 CEQGs. Supplementary information on the substance is also reviewed to assist with the
429 development and use of the CEQG. Literature searches should gather the following information:

430
431

- production and uses
- physical and chemical properties
- sources to aquatic environments
- environmental concentrations
- methods of quantification and current detection limits
- environmental fate, behaviour and persistence
- solubility of the substance in the various aquatic environments (freshwater and marine, hard versus soft water, pH and temperature influence, and so on)
- mobility of the substance and the compartments of the aquatic environment in which it is most likely to be present
- kinds of chemical and biological reactions that take place during transport and after deposit
- eventual chemical form under various environmental conditions
- persistence of the substance in water, sediment and biota
- toxic interactions with other substances (i.e., parameters affecting exposure and toxicity)
- bioaccumulation and biomagnification potential
- toxicokinetics and toxicodynamics
- mode of action.

432
433

434
435

436
437

438
439

440
441

442
443

444
445

446
447

448

For some chemicals there may be a lack of information regarding environmental fate and biological
449 consequences (e.g., mode of action). If no information is available on some of the above topics,
450 this should also be noted in the technical document.

451
452
453

454 **4.2 Environmental Concentrations**

455 Whenever possible, information on the environmental concentrations of the substance in sediment,
456 water and tissues from the three oceans bordering Canada should be summarized. This information
457 can be taken from the scientific literature and government reports. Where possible, spatial and
458 temporal variation should be noted to provide a full picture of trends and geographical distribution
459 of the substance.

460
461 It is important to recognize the influence of method detection limits (MDLs), sampling
462 methodology and analytical methods when characterizing environmental concentrations. The
463 MDL is defined as “the minimum concentration of a substance that can be measured and reported
464 with 99% confidence that the analyte concentration is greater than zero and is determined from
465 analysis of a sample in a given matrix containing the analyte” (Code of Federal Regulations [CFR]
466 2011). MDLs have typically decreased over time and historical results, reported as equal to or half
467 of the MDL, may lead to a misinterpretation of the data. Clear documentation should be provided
468 to describe how historical MDLs and outliers were treated in the analysis. Additionally, sampling
469 methodology and analytical methods will influence the final concentrations. Documenting these
470 methods will allow due appropriate consideration when making temporal or spatial comparisons.

471
472 For chemical mixtures such as PCBs and PBDEs, the specific congeners measured should be
473 noted. Comparisons across studies where chemical concentrations are expressed as the sum of a
474 chemical class, for example Σ PCBs, can be hindered by having a different sub-set of congeners.
475 Congeners can differ in toxicity and for some congeners, toxicity may not be known. A more
476 robust comparison can be made if the congener subset is documented.

477 478 479 **4.3 Analytical Methods**

480 A description of the analytical methods for substance quantification in environmental samples
481 should be included in the technical report. Any discrepancies between substance quantification
482 over the years (i.e., outdated methods) and differences between measurements in the lab vs the
483 field should be discussed. It is necessary to consider the MDL of the recommended analytical
484 method. Many organic chemicals require specialized high-resolution methods to detect levels
485 found in the ambient environment. These are often more costly than standard methods but are
486 necessary to quantify the concentrations of these chemicals. Some chemical groups are composed
487 of multiple congeners (e.g., PCBs, PBDEs); reporting the chemical concentrations in
488 environmental media should identify individual congeners whenever possible.

489 490 491 **4.4 Bioaccumulation Factors**

492 Bioaccumulation factors are necessary bioaccumulation metrics for calculating the Canadian water
493 quality guideline for the protection of marine mammals ($CWQG_{mm}$) and the Canadian sediment
494 quality guideline for the protection of marine mammals ($CSeQG_{mm}$) once the concentration in the
495 biota or prey tissue has been determined. Bioaccumulation factors are obtained from the literature
496 and can consider empirical data (i.e., field- or laboratory-derived estimates) and predicted data

497 from food web bioaccumulation models. The BAFs must be scientifically defensible and,
498 whenever possible, represent the conditions found in the three oceans bordering Canada.

499
500
501

4.5 Mode of Toxic Action

502 Information on the mode of toxic action (MoA) should be included to better understand how the
503 substance may affect the health endpoints of marine mammals (e.g., leading to immunotoxicity,
504 endocrine disruption, neurotoxicity and carcinogenesis). This review should extend across
505 mammalian species to identify endpoints that are biologically relevant to marine mammals. This
506 is especially important when data from laboratory animals are used to extrapolate the effects to
507 marine mammals. Many resources are available to help establish MoA, such as adverse outcome
508 pathways (AOP), key characteristics (KCs) frameworks, quantitative structure-activity
509 relationships (QSARs) and databases (e.g., EnviroTox).
510

With permission from the authors, Sections 5, 6 and 7 of this document in their entirety are reproduced from “A framework for the derivation of environmental quality guidelines that protect apex marine mammals from persistent organic pollutants (POPs)” (McTavish *et al.* 2024) with minor changes.

511

5. DERIVATION OF A TOXICITY REFERENCE VALUE FOR MARINE MAMMALS

5.1 What Is a Toxicity Reference Value and How Is It Derived?

512 A TRV is a parameter used to quantitatively assess potential risks to human health that are
513 associated with exposure to a chemical or contaminant of concern (Health Canada 2021b). TRVs
514 are published by various national and international agencies to characterize substance toxicity.
515 They can be derived by dividing the POD, which is the point in a toxicological dose-response data
516 set that generally corresponds to an estimated low- or no-effect level, by an uncertainty factor
517 (UF). UFs, also known as safety factors or assessment factors, are numerical factors applied to the
518 lowest value from an empirical toxicological data set for a given substance to account for various
519 uncertainties (Okonski *et al.* 2021).
520
521
522
523
524
525

526 Dose-response data for marine mammals are rarely available given the ethical, legal and logistical
527 constraints required to obtain them. Therefore, human health TRVs, which are extrapolated from
528 laboratory animal data sets (e.g., rats, mice, mink) (CCME 1998; United States Environmental
529 Protection Agency [US EPA] 2014), should be used as a starting point for selecting a POD.
530 Interspecies extrapolation is a process frequently used in human health risk assessment. Ross
531 (2000) and Ross and Birnbaum (2003) highlight the need for a WoE approach in marine mammals,
532 whereby the extrapolation of data from non-marine mammalian species to marine mammals is
533 appropriate owing to the similarities in physiological systems and mechanisms of toxicity among

534 mammals, the lack of controlled studies to determine effects thresholds for marine mammals, and
535 similar protection goals (protection of the individual) for humans and marine mammals. Thus, like
536 human risk assessment, it is reasonable to use the most conservative toxicity thresholds among
537 available mammalian studies when deriving TRVs for apex marine mammals.

538
539 If there is, however, evidence to suggest that an alternate endpoint is preferred given the
540 physiological, behavioural, ecological, and genetic or interspecies differences between marine
541 mammals and humans, then an alternate POD may be selected from the prepared database.

542 543 544 **5.2 Selection of a Point of Departure**

545
546 Two approaches are available for selecting a POD. The first, and most preferred, approach is to
547 use an existing POD from a human health TRV. If a human health TRV and corresponding POD
548 are not available or deemed inappropriate, a POD can be determined from a literature review.

549 550 *5.2.1. Selection of an Existing Point of Departure*

551
552 If available, human health TRVs can be used as a starting point for selecting a POD and associated
553 UFs for calculating a TRV for marine mammals (see Figure 1). Based on a toxicological dose-
554 response data set, a POD is identified as either a no- or low-effect level. Multiple endpoints may
555 be present in a toxicological data set (e.g., a benchmark dose lower confidence limit [BMDL]¹, a
556 no observed adverse effect level [NOAEL], a lowest observed adverse effect level [LOAEL], or a
557 maximum acceptable toxicant concentration [MATC]) and the selected POD is generally the
558 lowest value among these four endpoints. Human health TRVs² should be compiled from various
559 health agencies, including, but not limited to, Health Canada, the US EPA, California
560 Environmental Protection Agency, the World Health Organization, the Agency for Toxic
561 Substances and Disease Registry (ATSDR), the European Food Safety Authority and the
562 International Programme on Chemical Safety. If multiple human health TRVs are available, then
563 scientific judgement should be used to select the most appropriate one.

564 565 566 *5.2.2. Determination of a Point of Departure from Laboratory Dose-Response Data*

567
568 If a human health TRV and its corresponding POD is unavailable or deemed inappropriate, a POD
569 may be derived from the literature (Figure 1). This will involve collating and reviewing dose-
570 response toxicity data on surrogate mammals using the criteria for data quality described in
571 Appendix A. Once a toxicity database has been compiled, a POD is selected, which is generally
572 the most sensitive endpoint. Effects not previously noted in marine mammal studies may be
573 available in laboratory studies. However, given the similarities in mechanisms of toxicity across
574 mammals, these endpoints should not be discounted without justification. The selection of the final
575 POD should be done with the protection goal in mind, i.e., to be protective of individual marine
576 mammals.

¹ The benchmark dose (BMD, or its lower confidence limit, BMDL) is a dose that produces a predetermined change in the response rate of an adverse effect (e.g., 1%, 5% or 10% of response compared to control, depending on the severity of the endpoint) and is obtained by fitting dose-response data with mathematical models.

² Terminology may vary depending on the agency (e.g., tolerable daily intake (TDI), reference dose (RfD), minimal risk level (MRL)).

577 **5.2.3. Marine Mammal Biomonitoring Studies**

578
579 Marine mammal contaminant data, biomarker studies and meta-analyses that identify tissue
580 residue concentrations and the related physiological endpoints should be summarized. Although
581 the correlation in biomarker studies cannot be used to infer causality given the potential effects of
582 other factors, including exposure to other chemicals (chemical mixtures), several studies
583 systematically collated together can be used in a WoE approach to support the calculated CEOGs.
584

585
586 **5.3 Selection of Uncertainty Factors**

587
588 The UF is used to account for sources of uncertainty that cannot be estimated from the data set,
589 such as intraspecies variability including sensitive sub-populations, interspecies variability
590 including differences in toxicodynamics and toxicokinetics, and data quality and quantity.
591 Maximum UFs for each category are typically set at 10, though lower numbers are commonly used
592 and applied in a multiplicative manner (Stedeford *et al.* 2007). Toxicology data sets involving well
593 studied chemicals, marine mammals and sensitive endpoints may rely on fewer UFs or none at all.
594 Scientific judgement should be used to select an appropriate UF, and the rationale must be
595 documented. If more than one UF is needed, the selection of their values should be assessed
596 collectively rather than in isolation from the others.
597

598
599 **5.3.1. Intraspecies Variability**

600
601 To some degree, the BMF will account for the intraspecies uncertainty due to different life stages,
602 as all life stages are considered in the individual-based model (IBM) and the most sensitive life
603 stage is selected for the BMF (see Section 6.2). However, if evidence suggests that an additional
604 UF is warranted, the value should not exceed 10.
605

606
607 **5.3.2. Interspecies Variability**

608
609 While allometric scaling of acute toxicity data may be warranted to account for interspecies
610 differences, there is no evidence to support it for extrapolation of chronic toxicity data (Sample
611 and Arenal 1999). Its use has therefore been discouraged for extrapolating chronic endpoints
612 across species (Allard *et al.* 2010; Government of Canada 2013). Interspecies scaling is done by
613 using the ratio of food intake to body weight. If adequate scientific rationale exists to include a
614 further UF for interspecies extrapolation, then it should not exceed 10.
615

616
617 **5.3.3. Data Quality and Quantity**

618
619 Most agencies recommend the use of a UF to account for deficiencies in the toxicological data set.
620 Given that the original assessor will have the best understanding of the data set, the original UF
621 for data deficiency should be retained if a POD from a human health TRV is used. If a new database

622 is collated, the criteria in Appendix A should be used to assess the UF selection for toxicity
623 database deficiencies.

624
625

626 **5.4 Calculation of the Marine Mammal Toxicity Reference Value**

627

628 The selected POD, which is commonly reported as an oral dosage in food, must be adjusted to a
629 daily intake rate by including the body weight (bw in kg) and daily food ingestion (g per day) of
630 the test animal (see Equation 1).

631

632 **Equation 1.**
$$\text{PODdi} = \frac{\left[\left(\frac{\text{mg chemical}}{\text{kg food}} \right) \times \left(\frac{\text{g food}}{\text{d}} \right) \times \frac{1 \text{ kg}}{1,000 \text{ g}} \right]}{\text{kg bw}}$$

633

634 where:

635

636 PODdi = POD converted to daily intake in mg·kg⁻¹ bw per day

637 POD = selected NOAEL, BMDL or other endpoint reported as mg chemical·kg food⁻¹

638 bw = body weight in kg

639 d = day

640

641 Body weights and daily food ingestion, on a wet-weight basis, should be used from the toxicity
642 study from which the daily oral dose is reported. If these values are not available from the study,
643 they may be obtained from the literature (e.g., Banfield 1974; Dunning 1993; National Institute
644 for Occupational Safety and Health [NIOSH] 1993).

645

646 The final TRV is then calculated as:

647

648 **Equation 2.**
$$\text{TRV} = \frac{\text{POD}}{\text{UF}_1 \times \text{UF}_2 \times \dots \times \text{UF}_x}$$

649

650 where:

651

652 TRV = tolerable daily intake (mg·kg⁻¹ bw per day)

653 POD = selected NOAEL, BMDL or other endpoint adjusted to a daily intake rate in

654 Equation 1 and reported in mg·kg⁻¹ bw per day

655 UF = product of the uncertainty factors

656

657

658 **5.5 Consideration of Carcinogenic Effects**

659

660 Marine mammals exposed to carcinogenic pollutants are at risk of developing cancer over their
661 lifetime (Gulland *et al.* 2020; Newman and Smith 2006; Randhawa *et al.* 2015). The prevalence
662 of cancer in marine mammals chronically exposed to persistent organic pollutants (POPs) has been
663 reported for free-ranging populations (e.g., SRKW and SLEB) inhabiting highly contaminated
664 marine regions in the Northeastern Pacific Ocean and St. Lawrence Estuary (Gulland *et al.* 2020;
665 Randhawa *et al.* 2015; Raverty *et al.* 2020). As this protocol is concerned with protecting
666 individual marine mammals rather than populations, it is important to consider the carcinogenic

667 effects of the substance. As mentioned in Section 5.1, TRVs for non-cancer effects are determined
668 based on the threshold below which no adverse effects are expected. In cases where sufficient data
669 are available to demonstrate the occurrence of a threshold for cancer, the same procedure (POD
670 divided by a global UF) can be used to derive a TRV for cancer. Otherwise, by default, it is
671 assumed that any level of exposure to a carcinogenic substance is associated with a risk or
672 probability of developing cancer.

673
674 The corresponding TRV refers to a cancer slope factor (CSF,³ expressed in $\text{mg}\cdot\text{kg}^{-1}\text{bw}$ per day),
675 which can be converted into a risk-specific dose (RSD⁴, expressed in $\text{mg}\cdot\text{kg}^{-1}\text{bw}$ per day), as a
676 dose corresponding to a given incremental risk. In the context of guideline derivation, the
677 incremental risk is directly related to the protection objective (i.e., the incremental risk associated
678 with the guideline shall be deemed negligible or acceptable). For instance, in its guidance for
679 federal contaminated sites, Health Canada (2021a) considers that an incremental risk of 10^{-5} (one
680 in 100,000) is essentially negligible for humans, and in the United States, an incremental risk of
681 10^{-6} (one in 1,000,000) is retained as a regional screening value for potentially carcinogenic
682 chemicals (US EPA n.d.). To put these incremental risk values in perspective, the Canadian Cancer
683 Society estimates that four in 10 Canadians (risk of 0.4) are expected to develop cancer during
684 their lifetime (Canadian Cancer Society n.d.).


687 **6. ESTIMATING CONCENTRATIONS IN OTHER ENVIRONMENTAL** 688 **MEDIA**

690 **6.1. Overview**

691
692 Once the TRV has been established, empirical data or toxicokinetics (food web) bioaccumulation
693 models can be used to relate the TRV to the associated concentrations in prey tissue, water and
694 sediment. Protective prey tissue concentrations are derived by dividing the TRV by a BMF which
695 accounts for the biomagnification of the chemical in the marine mammal. Water concentrations
696 are calculated by dividing the concentration in the biota or prey tissue by a BAF and sediment
697 guidelines are derived by dividing the concentration in biota or the prey tissue by a biota-sediment
698 accumulation factor (BSAF) or by modelling the concentration in water and sediment using the
699 chemical properties of the substance (e.g., the fugacity ratio or equilibrium partitioning method).
700 This suite of bioaccumulation metric factors (i.e., BMF, BAF, BSAF) can be derived using field-
701 based or food web modelling approaches, or both. However, the uncertainty associated with
702 calculating the guidelines increases when moving away from the TRV. Thus, the uncertainty
703 associated with the sediment and water guidelines will be greater than the tissue diet guideline (see
704 Figure 2).

³ The CSF is a measurement of risk. It corresponds to the risk of developing cancer associated with a lifetime average exposure dose of $1\text{ mg}\cdot\text{kg}^{-1}\text{bw}$ per day (e.g., a CSF of 0.2 [$\text{mg}\cdot\text{kg}^{-1}\text{bw}$ per day] means that lifetime average exposure to $1\text{ mg}\cdot\text{kg}^{-1}\text{bw}$ per day may result in the development of cancer in one out of five individuals (a probability of 0.2, or 20%) exposed under these conditions.

⁴ The RSD is the dose associated with a given risk (probability) of developing cancer. For instance, a dose associated to a risk of 10^{-5} (i.e., a 10^{-5} RSD) of $0.00005\text{ mg}\cdot\text{kg}^{-1}\text{bw}$ per day means that one out of 100,000 individuals (risk or probability of 10^{-5} , i.e., 0.00001 or 0.001%) exposed over their lifetime to this average dose may develop cancer due to this substance. $\text{RSD} = \frac{\text{CSF}}{10^{-5}}$



COPY

706
707 **Figure 2. Pathways for the Derivation of Environmental Quality Guidelines for Prey**
708 **Tissue, Water and Sediment Starting with a Surrogate Toxicity Reference**
709 **Value**

710 **Notes:**

711 BAF = bioaccumulation factor; BMF = biomagnification factor; BSAF = biota-sediment accumulation factor; CDG_{mm} = Canadian dietary
712 guideline for the tissue of marine mammal prey; CSeQG_{mm} = Canadian sediment quality guideline for the protection of marine
713 mammals; CWQG_{mm} = water quality guideline for the protection of marine mammals; K_{oc} = organic carbon-water partition coefficient;
714 TRV = toxicity reference value; WoE = weight of evidence.

715 **6.2. Biomagnification Factor—Marine Mammal to Prey**

716
717 A BMF is the ratio of the chemical concentration in the tissue of a predator to the chemical
718 concentration in the tissue of the prey at the next lowest trophic level (Gobas *et al.* 2009; US EPA
719 2000). The ratio is unitless. For non-ionic chemicals and specific ionic chemicals with high K_{ow}
720 values, the concentrations should be lipid-normalized.⁵

721
722 BMFs are used to estimate the prey tissue concentration that will be protective of marine mammals.
723 The BMF estimates the concentration in marine mammal tissue that will occur after generations
724 of exposure to the contaminant. In marine mammals the body burden of contaminants accumulates
725 over a lifetime of exposure and calves are exposed to contaminants by way of placental and
726 lactational transfer (Barrett *et al.* 2021; Desforges *et al.* 2012; Lee *et al.* 2023). Although laboratory
727 feeding studies selected as the POD are typically chronic exposures, these are often for less than

⁵ Note that at the time of publication, lipid-normalized BMFs cannot be applied to per- and polyfluoroalkyl substances (PFAS) as these ionic substances mainly bond to the protein content or fraction of animal tissues.

728 one year and do not account for the long lifespans of marine mammals or for maternal transfer
729 exposures.

730
731 BMFs can be estimated from ecological models or field data, and these can be used together, as
732 modelled BMFs are often compared to field data for validation. If field-derived BMFs are
733 available, they can be considered in a WoE approach. Field-derived BMFs, based on empirical
734 tissue samples collected from predator and prey, can provide valuable estimates for guideline
735 derivation. However, the process of calculating field-derived BMFs comes with several
736 uncertainties and limitations, including high cost, lengthy time, legal restrictions and ethical
737 implications when working with threatened and endangered species. Due to sampling restrictions,
738 available data are limited to dart-biopsy (blubber tissue) sampling from free-ranging (wild) marine
739 mammals, if official authorized licence allows, or tissue samples opportunistically collected from
740 stranded animals or from subsistence harvests by Indigenous communities. As such, they may not
741 necessarily represent all life stages or health conditions present in the population.

742
743 For this protocol, it is recommended to use BMFs calculated using the IBM developed by Hickie
744 and others (Hickie *et al.* 2000; 2005; 2007; 2013). A major advantage of this model is that it does
745 not rely on ecosystem-specific input values, such as the contaminant concentration in fish, to
746 calculate a BMF for a specific species and substance. This allows the output of the models to be
747 applied to a wide range of contaminants without prior knowledge of concentrations in ecosystem
748 compartments. The IBM has been parameterized for three apex marine mammal species in Canada:
749 beluga whale (Hickie *et al.* 2000), killer whale (Hickie *et al.* 2007) and ringed seal (Hickie *et al.*
750 2005) which represent, respectively, the Atlantic, Pacific and Arctic oceans in Canada.

751
752 The IBM reconstructs temporal trends in marine mammals by considering the toxicokinetics of
753 the marine mammal (e.g., uptake, distribution, elimination) and life history characteristics and
754 calculates the tissue concentration in the marine mammal at specific time intervals over its lifespan,
755 including the contaminant burden of offspring due to placenta transfer and nursing. The model
756 loops upon itself until the contaminant concentrations reach a steady state. In this way, the model
757 presents a multi-generation scenario (Hickie *et al.* 2007). The model produces multiple predicted
758 BMFs for each sub-population (i.e., time-dependent for calves or pups, juveniles, adult females
759 and adult males) for the three species. The mean calf or pup value was selected to be protective of
760 each respective species.

761
762 For this protocol, the overall mean calf or pup BMF for killer whales, beluga whales and Arctic
763 ringed seals was chosen as a surrogate for marine mammal BMF (see Table 1). These marine
764 species were chosen as surrogates for the other species of apex marine mammals representative of
765 the three oceans bordering Canada, to which was applied the most recent bioaccumulation IBM
766 that includes Kow-dependent terms. When considering life history traits, the selection of the killer
767 whale is a suitable surrogate given that orca whales have the longest birth intervals (five years for
768 killer whales versus three years for beluga whales and one year for ringed seals). This means orca
769 females have the longest period to accumulate a contaminant burden between births, which is then
770 transferred to the orca calf via maternal transfer. Further, seals are known to have a greater capacity
771 to biotransform organic chemicals such as PCBs, which leads them to having lower BMFs.

772

773 Kow-specific equations were estimated from field data for PCBs for uptake efficiency from prey
 774 (McLachlan 1994) and partitioning to the milk (Cadioux *et al.* 2016). Field data for PCBs and
 775 PBDEs were used to estimate Kow-specific equations for partitioning to the fetus (Desforges *et al.*
 776 2012). These biological processes (i.e., digestion, gestation and lactation) are not the result of
 777 simple equilibrium partitioning. They require multiple steps, which occur in both aqueous and
 778 lipid states. Therefore, contrary to the positive relationship between Kow and concentration in
 779 lipids, there is an inverse relationship between Kow and uptake efficiency, partitioning to fetus and
 780 partitioning to the milk (Cadioux *et al.* 2016; Desforges *et al.* 2012; McLachlan 1994). These
 781 relationships have not been tested for other POPs but, aside from PFAS that accumulates in
 782 proteins, it is anticipated that they will be similar across other lipophilic contaminants (Hickie pers.
 783 com. 2023).

784
 785 **Table 1. Mean Calf or Pup BMFs (Wet-Weight-Based) for a Range of Kow Values**
 786

Log Kow	Arctic ringed seals (<i>Pusa hispida</i>)	Beluga whales (<i>Delphinapterus leucas</i>)	Killer whales (<i>Orcinus orca</i>)
5	271	719	909
5.2	271	722	910
5.4	271	722	910
5.6	275	718	903
5.8	272	711	894
6	265	699	879
6.2	255	680	857
6.4	241	654	825
6.6	224	617	779
6.8	201	569	714
7	179	504	630
7.2	149	425	524
7.4	117	334	404
7.6	85	242	285
7.8	55	159	181
8.0	33	95	104

Log K _{ow}	Arctic ringed seals (<i>Pusa hispida</i>)	Beluga whales (<i>Delphinapterus leucas</i>)	Killer whales (<i>Orcinus orca</i>)
8.2	17	52	55
8.4	8.5	27	28

Notes

BMFs were estimated using the IBM (Hickie *et al.*, 2000; 2005; 2007; 2013) that was updated to include K_{ow}-specific equations for contaminant assimilation from prey and contaminant partitioning to milk and fetus. Input values for the IB model are given in Appendix B. The input values include the assumption of negligible rates of biotransformation.

6.3. Bioaccumulation Factor—Prey to Water

The BAF is the ratio of contaminant concentration in the tissue of an organism (e.g., aquatic biota or the prey of marine mammals) to the contaminant concentration in water or the aquatic environment (Gobas *et al.* 2009) expressed in units of L·kg tissue on a wet-, dry- or lipid-weight basis. The BAF approach is predicated on the following assumptions: both the organism and its food are exposed to the same concentration of contaminant in the water and the exposure concentration does not change substantially over time (i.e., steady state). Depending on the type of chemical and its properties, BAFs can be measured or predicted using one or more of the following methods:

- Measured BAFs derived from data obtained from a field study (i.e., field-measured BAFs, or trophic magnification factors [TMFs])
- BAFs derived from laboratory measurements
- Predicted BAFs from models (e.g., AQUAWEB).

Field studies should be reviewed to ensure that the substance under investigation has reached a steady state in the aquatic ecosystem or that water concentrations were averaged over a duration that is comparable to the time required for the substance to reach a steady state (US EPA, 2000). Further, the study should be examined to ensure the aqueous concentrations were measured accurately, especially in older studies where cross-contamination may have artificially increased BAF values (Borga *et al.* 2005).

The selection of a BAF involves collating literature values and selecting a value that is representative of each of the ocean regions where differences are noted. The final value selected will be the most conservative of the values to ensure the final CEQGs (CEQGs_{mm}) are protective for all apex marine mammal predators.

TMFs represent the “diet-weighted average BMF of chemical residues across food webs” (Burkhard *et al.* 2013). They are typically derived from the anti-log of the regression slope of the log of lipid-normalized chemical concentrations in organisms versus a spanning range of species trophic levels, which are determined from stable isotope ($\delta^{15}\text{N}$) data (Borga *et al.* 2012). A recent review by Kidd *et al.* (2019) provides practical guidance on TMF use and selection for environmental quality guideline derivation, including considering the following criteria when determining the reliability of TMF estimates:

- 829 • a minimum of two or three trophic levels
- 830 • measured contaminant concentrations in whole organisms
- 831 • lipid-normalizing concentrations of organic contaminants
- 832 • the inclusion of several lower trophic level invertebrate taxa (e.g., zooplankton, benthic
- 833 invertebrates)
- 834 • a balanced number of samples across trophic levels
- 835 • adequate and balanced samples for each trophic level
- 836 • the inclusion of organisms known to be linked by diet through the food web
- 837 • measured contaminant concentrations above detection limits in all samples
- 838 • all sampled organisms collected within a similar time frame (e.g., one season)
- 839 • caution for potential upward bias of TMF estimates if homeotherms and air-breathing
- 840 organisms (i.e., birds and mammals) are included in the data set.

841
842 If using TMFs, the final step is to estimate the BAF of the contaminant from water to plankton.
843 Chemical-specific information for the BAF (either laboratory or field measurements) is preferable
844 to assuming equilibrium, but if no chemical-specific information is available then the equilibrium
845 approach is acceptable. The final BAF for prey to water will then be the product of the
846 $TMF_{prey:plankton}$ and the $BAF_{plankton:water}$:

$$847 \text{Equation 3. } BAF_{prey:water} = [TMF_{prey:plankton}] \times [BAF_{plankton:water}]$$

850 851 **6.4. Estimating Sediment Concentrations**

852
853 Sediment concentrations can be estimated in two ways: either using the equilibrium partitioning
854 approach, which estimates the bulk sediment concentration from the water concentration based on
855 the organic carbon-water partition coefficient (K_{oc}) (DiToro *et al.* 1991), or by using the BSAF,
856 which is the ratio of the contaminant concentration in the tissue (on a wet-weight or lipid-
857 normalized basis) of an organism to the contaminant concentration in the sediment (on a dry-
858 weight basis or a total organic carbon (TOC) content-normalized basis) (Alava *et al.* 2012;
859 Arblaster *et al.* 2015). Each of these methods are described in this section.

860
861 The equilibrium partitioning approach is applicable to non-ionic organic chemicals and assumes
862 that the concentration between the organic carbon content of the sediment and the sediment pore
863 water are in equilibrium (Di Toro *et al.* 1991). If the concentration in the water is known, an
864 estimate of the concentration in sediment organic carbon can be calculated using the organic
865 carbon-water partitioning coefficient and the percentage of organic carbon in the sediment.

866
867 Alternatively, a BSAF can be used to back-calculate the concentration in the sediment given a
868 known concentration in a biota. A BSAF can be measured either in the laboratory or in the field.
869 Field measurements done on migratory or wide-ranging species can add challenges, as
870 contaminants can be accumulated from other locations. BSAFs are most applicable to site-specific
871 assessments using sessile organisms. However, this bioaccumulation metric has been applied to
872 marine mammals (e.g., southern resident killer whales) and their critical habitat (e.g., Alava *et al.*
873 2012; Arblaster *et al.* 2015; Lachmuth *et al.* 2010) and has the advantage of integrating biological
874 processes not considered in the equilibrium approach. Like BAFs, a review is necessary to ensure

875 that the aquatic ecosystem is at equilibrium and that the appropriate analytical methods were used
876 to prevent cross-contamination.

877
878 The BSAF is calculated as:

879
880 **Equation 4.** $BSAF = \frac{C_t}{C_s}$

881
882 where:

883
884 BSAF = the biota-sediment accumulation factor
885 C_t = concentration of chemical in the biota species ($\text{g}\cdot\text{kg}^{-1}$ wet weight)
886 C_s = concentration of contaminant in the sediment ($\text{g}\cdot\text{kg}^{-1}$ dry weight) (Alava *et al.* 2012;
887 Arblaster *et al.* 2015)

888
889 The BSAF can also be normalized in terms of lipid content and TOC fraction in the sediment, and
890 the resulting units for C_t and C_s become $\text{g}\cdot\text{kg}^{-1}$ lipid in biota and $\text{g}\cdot\text{kg}^{-1}$ organic carbon [OC] in
891 sediment, respectively (Alava *et al.* 2012; Arblaster *et al.* 2015).

892
893 Whenever possible, BSAFs should be used over the equilibrium approach. If using the BSAF
894 approach, values should be collated for the three oceans bordering Canada. If BSAFs are not
895 available for all three oceans and uncertainty exists as to its application to the remaining oceans,
896 then the lower value of the two approaches (equilibrium partitioning vs BSAF) should be chosen.

897 898 899 **6.5. Criteria for Other Models**

900
901 It is possible that a model other than the IBM or AQUAWEB—applied for BMF and BAF
902 predictions, respectively—may be required due to properties of the contaminant. In these
903 situations, the model selected should meet the following criteria:

- 904 • The model is well established and cited in the peer-reviewed literature.
- 905 • Code and equations are transparent and publicly available.
- 906 • Chemical or physical properties of the chemical are explicitly included in the model or are
907 available from a reputable source, including:
 - 908 ○ K_{ow}
 - 909 ○ Octanol-air partition coefficient (K_{OA})
 - 910 ○ Sediment-to-water concentration ratio
- 911 • Site-specific environmental parameters of the ecosystem are assessed, including:
 - 912 ○ mean water temperature
 - 913 ○ concentration of particulate organic carbon in the water
 - 914 ○ concentration of dissolved organic carbon in the water
 - 915 ○ concentration of suspended solids in the water
 - 916 ○ organic carbon content of the sediment (TOC content)
 - 917 ○ chemical concentration in the water
 - 918 ○ chemical concentration in the sediment (water temperature, salinity, pH)
- 919 • There is a sufficient quantity and quality of contaminant data for abiotic compartments
920 (sediment and water).

- There is a reliable understanding of the composition and structure of the food web and dietary preferences of organisms.
- Site-specific biological properties and life history characteristics of biota are included (organism lipid content, dietary uptake rate, growth rate, organism wet weight or volume, diet percentage or organism feeding preferences).
- Empirical data are available for biota (upper trophic level or apex predators) to test the performance of the model (model bias).

Food web bioaccumulation models meeting these modelling criteria are available and have been developed and applied for marine regions and ecosystems of the Northeastern Pacific, including British Columbia (Canada) and San Francisco Bay (California, United States) [see the supporting or supplementary information data sets published in Alava *et al.* 2012; Alava *et al.* 2016; Gobas and Arnot 2010].

7. CALCULATION OF THE FINAL CANADIAN ENVIRONMENTAL QUALITY GUIDELINES

7.1. Dietary Guideline

The Canadian dietary guideline (CDG_{mm}) for the tissue of marine mammal prey is an expected tissue residue concentration to be protective of apex marine mammals. When using field data or species-specific models for the species deemed to be most sensitive, resulting BMFs may be used directly to determine the CDG_{mm}. The rate of food intake to body weight (FI:BW) for the species-specific BMF is used to convert the daily dietary dose to a dietary tissue concentration (CCME 1998) [see Equation 5]. In Appendix B, Table 3 provides a list of FI:BW rates for the mammalian species from Table 1.

The CDG_{mm} is calculated using the following equation:

$$\text{Equation 5. } CDG_{mm} = \left(\frac{TRV}{(FI:BW) \times BMF} \right)$$

where:

CDG_{mm} = the Canadian dietary guideline protective of marine mammals (mg·kg⁻¹ wet weight diet)

TRV = toxicity reference value established in Section 5 (mg·kg⁻¹ bw per day)

FI:BW = ratio of food intake (kg wet weight diet per day) to body weight (kg bw) for the same species as the selected BMF

BMF = biomagnification factor established in Section 6.2 (unitless)

962 7.2. Water Quality Guideline

963

964 The CWQG_{mm} is calculated using the following equation:

965

966 **Equation 6.**
$$CWQG_{mm} = \frac{CDG_{mm}}{BAF_{prey:water}}$$

967

968 where:

969

970 CWQG_{mm} = Canadian water quality guideline protective of marine mammals (mg·L⁻¹)

971 CDG_{mm} = Canadian dietary guideline established in Section 7.1. (mg·kg⁻¹ wet weight)

972 BAF_{prey:water} = bioaccumulation factor established in Section 6.3 (L·kg⁻¹ wet weight)

973

974

975 7.3. Sediment Quality Guideline

976

977 The CSeQG_{mm} can be calculated using the equilibrium partitioning approach (DiToro *et al.* 1991)
978 or using the BSAF (Alava *et al.* 2012; Arblaster *et al.* 2015). See Section 6.4 for a discussion of
979 these approaches.

980

981 Sediment concentrations can be calculated with the equilibrium partitioning approach using the
982 following equation:

983

984 **Equation 7.**
$$CSeQG_{mm} = CWQG_{mm} \times K_{oc} \times \%OC$$

985

986 where:

987

988 CSeQG_{mm} = Canadian sediment quality guideline protective of marine mammals (mg·kg⁻¹
989 dry weight sediment)

990 CWQG_{mm} = Canadian water quality guideline protective of marine mammals (mg·L⁻¹)

991 K_{oc} = organic carbon-water partition coefficient for the substance (L·kg⁻¹)

992 % OC = percentage of organic carbon adjustment (typically to 1% to provide a conservative
993 benchmark against which to compare monitoring data)

994

995 Before making comparisons to the CSeQG_{mm}, monitoring data must be normalized to 1% OC to
996 assess whether the guideline value is exceeded.

997

998 The following equation can be used to calculate the CSeQG_{mm} using the BSAF (adapted from
999 Alava *et al.* 2012; Arblaster *et al.* 2015):

1000

1001 **Equation 8.**
$$CSeQG_{mm} = \frac{CDG_{mm}}{BSAF}$$

1002 where:

1003

1004 CSeQG_{mm} = Canadian sediment quality guideline protective of marine mammals (mg·kg⁻¹
1005 sediment)

1006 CDG_{mm} = Canadian dietary guideline established in Section 7.1 (mg·kg⁻¹ wet weight diet)

1007 BSAF = biota-sediment accumulation factor (kg OC sediment/kg lipid biota or kg dry
1008 weight sediment/kg wet weight biota)

1009
1010

1011 **7.4. Weight-of-Evidence Review**

1012

1013 A WoE approach is generally understood as a method for decision-making that involves
1014 consideration of multiple sources of information and lines of evidence. A WoE framework has
1015 been espoused for marine mammals, where cause-and-effect studies are lacking and extrapolation
1016 from other mammals (e.g., lab rodents) offers a resolution to such information gaps (Ross 2000).
1017 A WoE approach avoids relying solely on any one piece of information or line of evidence. A
1018 WoE approach may be applied at various stages of guideline development. It can be used to
1019 evaluate the quality of a single study, to assess similar studies for a particular parameter or
1020 endpoint, or to integrate information across multiple lines of evidence to support the choice of the
1021 CEQG_{mm}. If it is not possible to follow the steps outlined in this protocol, a WoE review should
1022 be completed that outlines all the lines of evidence compiled and considered that lead to the
1023 CEQG_{mm}.

1024

1025 Contaminant data from marine mammals is one line of evidence that can be used to assess the
1026 calculated guidelines. Although field studies cannot establish a clear causal effect given the
1027 presence of other contaminants and stressors, correlations between marine mammal tissue
1028 concentrations and a variety of effects (hormone levels, genetic markers, immunological endpoints
1029 and blood chemistry; or population-level data such as pregnancy failure, lower birth rate, decreased
1030 survivability and population decrease) together with observations from captive feeding studies do
1031 strongly suggest a relationship (e.g., Mos *et al.* 2010). The BMF values can be used to predict the
1032 concentration in blubber if marine mammals are exposed to the chemical concentration equal to
1033 the CDG_{mm}. Ideally, the CDG_{mm} would predict a biomonitored concentration lower than that found
1034 in the marine mammals in which an effect has occurred.

1035 **REFERENCES**

- 1036 Alava, J. J., and Gobas, F. 2012. Assessing biomagnification and trophic transport of persistent organic pollutants in
1037 the food chain of the Galápagos sea lion (*Zalophus wollebaeki*): conservation and management implications.
1038 In *New Approaches to the Study of Marine Mammals*, A. Romero and E. O. Keith (Eds). Rijeka: InTech, pp.
1039 77–108.
- 1040
- 1041 Alava, J.J., Ross, P.S., Lachmuth, C.L., Ford, J.K.B., Hickie, B., and Gobas, F.A.P.C. 2012. Habitat-based PCB
1042 Environmental Quality Criteria for the protection of endangered killer whales (*Orcinus orca*). *Environ. Sci.*
1043 *Technol.* **46**: 12655–12663.
- 1044
- 1045 Alava, J.J., Ross, P.S., and Gobas, F.A.P.C. 2016. Food web bioaccumulation model for resident killer whales from
1046 the Northeastern Pacific Ocean as a tool for the derivation of PBDE-Sediment Quality Guidelines. *Arch.*
1047 *Environ. Contam. Toxicol.* **70**(1): 155–168. doi: 10.1007/s00244-015-0215-y
- 1048
- 1049 Alava, J.J., Cisneros-Montemayor, A.M., Sumaila, R., and Cheung, W.W.L. 2018. Projected amplification of food
1050 web bioaccumulation of MeHg and PCBs under climate change in the Northeastern Pacific. *Scientific*
1051 *Reports* **8**: 13460. doi:10.1038/s41598-018-31824-5
- 1052
- 1053 Allard, P., Fairbrother, A., Hope, B.K., Hull, R.N., Johnson, M.S., Kapustka, L., Mann, G., McDonald, B., and Sample,
1054 B.E. 2010. Recommendations for the development and application of wildlife toxicity reference values.
1055 *Integr. Environ. Assess. Manag.* **6**(1): 28–37. doi: 10.1897/IEAM_2009-010.1
- 1056
- 1057 Arblaster, J., Ikonou, M.G., and Gobas, F.A. 2015. Toward ecosystem-based Sediment Quality Guidelines for
1058 polychlorinated biphenyls (PCBs). *Integr. Environ. Assess. Manag.* **11**(4): 689–700.
- 1059
- 1060 Banfield, A.W.F. 1974. The mammals of Canada. National Museums of Canada. University of Toronto Press, Toronto.
- 1061
- 1062 Barrett, H., Du, X., Houde, M., Lair, S., Verreault, J., and Peng, H. 2021. Suspect and nontarget screening revealed
1063 class-specific temporal trends (2000-2017) of poly- and perfluoroalkyl substances in St. Lawrence beluga
1064 whales. *Environ. Sci. Technol.* **55**: 1659–1671.
- 1065
- 1066 BC ENV (British Columbia Ministry of Environment and Climate Change Strategy). 2019. Derivation of water quality
1067 guidelines for the protection of aquatic life in British Columbia. Water Quality Guideline Series, WQG-06.
1068 Prov. B.C., Victoria B.C.
- 1069
- 1070 British Columbia Ministry of Environment and Climate Change Strategy (BC ENV). 2021. Guidance for the
1071 Derivation of Water Quality Objectives in British Columbia, WQO-04. Prov. B.C., Victoria B.C.
- 1072
- 1073 Borgå, K., Fisk, A.T., Hargrave, B., Hoekstra, P.F., Swackhamer, D., and Muir, D.C. 2005. Bioaccumulation factors
1074 for PCBs revisited. *Environ. Sci. Technol.* **39**(12): 4523–4532.
- 1075
- 1076 Borgå, K., Kidd, K.A., Muir, D.C.G., Berglund, O., Conder, J.M., Gobas, F.A.P.C., Kucklick, J., Malm, O., and
1077 Powell, D.E. 2012. Trophic magnification factors: Considerations of ecology, ecosystems and study design.
1078 *Integr. Environ. Assess. Manag.* **8**: 64–84.
- 1079
- 1080 Burkhard, L.P., Borgå, K., Powell, D.E., Leonards, P., Muir, D.C.G., Parkerton, T.F., and Woodburn, K.B. 2013.
1081 Improving the quality and scientific understanding of trophic magnification factors (TMFs). *Environ. Sci.*
1082 *Technol.* **47**: 1186–1187.
- 1083
- 1084 Cadieux, M.A., Muir, D.C.G., Beland, P., and Hickie, B.E. 2016. Lactational transfer of polychlorinated-biphenyls
1085 (PCBs) and other organochlorines in St. Lawrence beluga whales (*Delphinapterus leucas*). *Arch. Environ.*
1086 *Contam. Toxicol.* **70**: 169–179.
- 1087
- 1088 Canadian Cancer Society. (n.d.) Cancer statistics at a glance. <https://cancer.ca/en/research/cancer-statistics/cancer-statistics-at-a-glance>.

- 1088 CCME (Canadian Council of Ministers of the Environment). 1995. Protocol for the derivation of Canadian sediment
1089 quality guidelines for the protection of aquatic life. Winnipeg, Manitoba. [http://ceqg-
1091 rcqe.ccme.ca/download/en/226/](http://ceqg-
1090 rcqe.ccme.ca/download/en/226/).
- 1092 CCME (Canadian Council of Ministers of the Environment). 1998. Protocol for the derivation of Canadian tissue
1093 residue guidelines for the protection of wildlife that consume aquatic biota. Winnipeg, Manitoba. [http://ceqg-
1095 rcqe.ccme.ca/download/en/290/](http://ceqg-
1094 rcqe.ccme.ca/download/en/290/).
- 1096 CCME (Canadian Council of Ministers of the Environment). 2001. Canadian tissue residue guidelines for the
1097 protection of wildlife consumers of aquatic biota: Polychlorinated biphenyls (PCBs). Updated. In: Canadian
1098 environmental quality guidelines, 1999, Canadian Council of Ministers of the Environment. Winnipeg,
1099 Manitoba. [https://ccme.ca/en/res/polychlorinated-biphenyls-pcbs-canadian-tissue-residue-guidelines-for-
1101 the-protection-of-wildlife-consumers-of-aquatic-biota-en.pdf](https://ccme.ca/en/res/polychlorinated-biphenyls-pcbs-canadian-tissue-residue-guidelines-for-
1100 the-protection-of-wildlife-consumers-of-aquatic-biota-en.pdf).
- 1102 CCME (Canadian Council of Ministers of the Environment). 2003. Guidance on the Site-Specific Application of
1103 Water Quality Guidelines in Canada: Procedures for Deriving Numerical Water Quality Objectives.
1104 [https://ccme.ca/en/res/guidance-on-the-site-specific-application-of-water-quality-guidelines-in-canada-
1106 en.pdf](https://ccme.ca/en/res/guidance-on-the-site-specific-application-of-water-quality-guidelines-in-canada-
1105 en.pdf).
- 1107 CCME (Canadian Council of Ministers of the Environment). 2007. A protocol for the derivation of water quality
1108 guidelines for the protection of aquatic life 2007. In: Canadian environmental quality guidelines, 1999,
1109 Canadian Council of Ministers of the Environment. Winnipeg, Manitoba. [https://ccme.ca/en/res/protocol-
1111 for-the-derivation-of-water-quality-guidelines-for-the-protection-of-aquatic-life-2007-en.pdf](https://ccme.ca/en/res/protocol-
1110 for-the-derivation-of-water-quality-guidelines-for-the-protection-of-aquatic-life-2007-en.pdf).
- 1112 CCREM (Canadian Council of Resource and Environment Ministers). 1987. Canadian water quality guidelines.
1113 Prepared by the Task Force on Water Quality Guidelines of the Canadian Council of Resource and
1114 Environment Ministers, Toronto, ON.
- 1115
- 1116 CFR (Code of Federal Regulations), 2011. Appendix B to Part 136 – Definition and procedure for the determination
1117 of the method detection limit – Revision 1.11.
- 1118 COSEWIC (Committee on the Status of Endangered Wildlife in Canada). 2018. COSEWIC assessment and status
1119 report on the polar bear *Ursus maritimus* in Canada. Ottawa. Xv + 113 pp.
1120 [https://www.canada.ca/en/environment-climate-change/services/species-risk-public-registry/cosewic-
1122 assessments-status-reports/polar-bear-2018.html](https://www.canada.ca/en/environment-climate-change/services/species-risk-public-registry/cosewic-
1121 assessments-status-reports/polar-bear-2018.html).
- 1123 De Guise, S., Martineau, D., Béland, P., and Fournier, M. 1995. Possible mechanisms of action of environmental
1124 contaminants on St. Lawrence beluga whales (*Delphinapterus leucas*). Environ. Health. Perspect. **103**: 73–
1125 77. doi:10.1289/ehp.95103s473
- 1126
- 1127 Desforges, J.-P.W., Ross, P.S., and Loseto, L.L. 2012. Transplacental transfer of polychlorinated biphenyls and
1128 polybrominated diphenyl ethers in Arctic beluga whales (*Delphinapterus leucas*). Environ. Toxicol. Chem.
1129 **31**: 296–300.
- 1130
- 1131 Desforges, J.-P.W., Sonne, C., Levin, M., Siebert, U., De Guise, S., and Dietz, R. 2016. Immunotoxic effects of
1132 environmental pollutants in marine mammals. Environ. Int. **86**: 126–139. doi: 10.1016/j.envint.2015.10.007
- 1133
- 1134 DFO (Fisheries and Oceans Canada). 2018. Recovery strategy for the northern and southern resident killer whales
1135 (*Orcinus orca*) in Canada [Proposed]. Species at Risk Act Recovery Strategy Series, Fisheries and Oceans
1136 Canada, Ottawa.
- 1137
- 1138 Di Toro, D.M., Zarba, C.S., Hansen, D.J., Berry, W.J., Swartz, R.C., Cowan, C.E., Pavlou, S.P., Allen, H.E., Thomas,
1139 N.A., and Paquin, P.R. 1991. Technical basis for establishing sediment quality criteria for nonionic organic
1140 chemicals using equilibrium partitioning. Environ. Toxicol. Chem. **10**(12): 1541–1583.
- 1141
- 1142 Dunning, J.B. 1993. CRC handbook of avian masses. CRC Press, Boca Raton, Florida.

1143 Emmerich, C.H. and Harris, C.M., 2019. Minimum information and quality standards for conducting, reporting, and
1144 organizing in vitro research. Bepalov A., Michel M., and Steckler T. Cham: Springer, 257, pp.177-96.
1145

1146 Fair, P.A., and Houde, M. 2023. Chapter 3.2.5 - Environmental endocrine-disrupting chemicals and their effects in
1147 marine mammals. *In* Environmental Contaminants and Endocrine Health. *Edited by* O. Carnevali and G.
1148 Hardiman. Elsevier Inc., Academic Press. pp. 283-306. doi: 10.1016/B978-0-12-824464-7.00017-9.
1149

1150 Gobas, F.A.P.C., and Arnot, J. 2010. Food web bioaccumulation model for polychlorinated biphenyls in San
1151 Francisco Bay, California, USA. *Environ. Toxicol. Chem.* **29**: 1385–1395.
1152

1153 Gobas, F.A.P.C., de Wolf, W., Verbruggen, E., Plotzke, K., and Burkhard, L., 2009. Revisiting bioaccumulation
1154 criteria for POPs and PBT assessments. *Integr. Environ. Assess. Manag.* **5**: 624–637.
1155 https://setac.onlinelibrary.wiley.com/doi/abs/10.1897/IEAM_2008-089.1.
1156

1157 Government of Canada. 2000. Canadian Environmental Protection Act: Persistence and Bioaccumulation Regulations,
1158 P.C. 2000-348, 23 March, 2000, SOR/2000-107. Canada Gazette, Part II, vol. 134, no. 7, pp. 607–612.
1159 Ottawa, Ontario. <https://publications.gc.ca/gazette/archives/p2/2000/2000-03-29/pdf/g2-13407.pdf>.
1160

1161 Government of Canada. 2013. Federal Contaminated Sites Action Plan (FCSAP): Ecological risk assessment
1162 guidance, module 2: Selection or development of site-specific toxicity reference values. Ottawa, Ontario.
1163 https://publications.gc.ca/collections/collection_2014/ec/En14-92-2-2013-eng.pdf.
1164

1165 Gulland, F., Hall, A.J., Ylitalo, G.M., Colegrove, K.M., Norris, T., Duignan, P.J., Halaska, B., Acevedo Whitehouse,
1166 K., Lowenstine, L.J., Deming, A.C., and Rowles, T.K., 2020. Persistent contaminants and herpesvirus OthV1
1167 are positively associated with cancer in wild California sea lions (*Zalophus californianus*). *Front. Mar. Sci.*
1168 **7**: 602565. doi :/10.3389/fmars.2020.602565
1169

1170 Health Canada. 2021a. Federal contaminated site risk assessment in Canada: Guidance on human health preliminary
1171 quantitative risk assessment (PQRA), version 3.0. https://publications.gc.ca/collections/collection_2021/sc-hc/H129-114-2021-eng.pdf.
1172
1173

1174 Health Canada. 2021b. Federal contaminated site risk assessment in Canada: Toxicological reference values (TRVs),
1175 Version 3.0. https://publications.gc.ca/collections/collection_2021/sc-hc/H129-108-2021-eng.pdf.
1176

1177 Helle, E., Olsson, M., and Jensen, S. 1976. DDT and PCB levels and reproduction in ringed seal from the Bothnian
1178 Bay. *Ambio* **5**: 188–189.
1179

1180 Hickie, B.E., Cadieux, M.A., Richl, K.N., Gregory, D.B., Alava, J.J., and Fair, P.A. 2013. Modeling PCB
1181 bioaccumulation in the bottlenose dolphin (*Tursiops truncatus*): Estimating a dietary threshold concentration.
1182 *Environ. Sci. Technol.* **2103**(47): 12314–12324.
1183

1184 Hickie, B.E., Kingsley, M.C.S., Hodson, P.V., Muir, D.C.G., Béland, P., and Mackay, D. 2000. A modelling-based
1185 perspective on the past, present, and future polychlorinated biphenyl contamination of the St. Lawrence
1186 beluga whale (*Delphinapterus leucas*) population. *Fish. Aquat. Sci.* **57**: 101–112.
1187

1188 Hickie, B.E., Muir, D.C.G., Addison, R.F., and Hoekstra, P.F. 2005. Development and application of bioaccumulation
1189 models to assess persistent organic pollutant temporal trends in Arctic ringed seal (*Phoca hispida*)
1190 populations. *Sci. Total. Environ.* **351–352**: 413–426.
1191

1192 Hickie, B.E., Ross, P.S., Macdonald, R.W., and Ford, J.K.B. 2007. Killer whales (*Orcinus orca*) face protracted health
1193 risks associated with lifetime exposure to PCBs. *Environ.Sci.Technol.* **41**: 6613–6619.
1194

1195 Kidd, K.A., Burkhard, L.P., Babut, M., Borgå, K., Muir, D.C., Perceval, O., Ruedel, H., Woodburn, K. and Embry,
1196 M.R. 2019. Practical advice for selecting or determining trophic magnification factors for application under
1197 the European Union Water Framework Directive. *Integr. Environ. Assess. Manag.* **15**(2):266–277.
1198

- 1199 Lachmuth, C.L., Alava, J.J., Hickie, B.E., Johannessen, S.C., Macdonald, R.W., Ford, J.K.B., Ellis, G.M., Gobas,
1200 F.A.P.C., and Ross, P.S. 2010. Ocean disposal in resident killer whale (*Orcinus orca*) critical habitat: Science
1201 in support of risk management. DFO Can. Sci. Advis. Sec. Res. Doc. 2010/116.
1202
- 1203 Lee, K., Alava, J.J., Cottrell, P., Cottrell, L., Grace, R., Zysk, I., and Raverty, S. 2023. Emerging contaminants and
1204 new POPs (PFAS and HBCDD) in endangered southern resident and Bigg's (transient) killer whales (*Orcinus*
1205 *orca*): In utero maternal transfer and pollution management implications. Environmental Science &
1206 Technology **57**(1): 360–374. doi: 10.1021/acs.est.2c04126.
1207
- 1208 McLachlan, M.S. 1994. Model of the fate of hydrophobic contaminants in cows. Environ Sci Technol. **28**: 2407–2414.
1209
- 1210 McTavish, K., Alava, J.J., Brown, T., Crossland, M., Dangerfield, N., Hickie, B., Ross, P.S., and Tillmanns, A. 2024.
1211 A framework for the derivation of environmental quality guidelines that protect apex marine mammals from
1212 persistent organic pollutants (POPs). Can. Tech. Rep. Fish. Aquat. Sci. 3582.
1213
- 1214 Mos, L., Cameron, M., Jeffries, S.J., Koop, B.F., and Ross, P.S. 2010. Risk-based analysis of PCB toxicity in harbour
1215 seals. Integr. Environ. Assess. Manag. **6**: 631–640.
1216
- 1217 Myatt, G.J., Ahlberg, E., Akahori, Y., Allen, D., Amberg, A., Anger, L.T., Aptula, A., Auerbach, S., Beilke, L.,
1218 Bellion, P., and Benigni, R. 2018. In silico toxicology protocols. Regul. Toxicol. Pharmacol. **96**: 1–17.
1219
- 1220 Newman, S.J., and Smith, S.A. 2006. Marine mammal neoplasia: A review. Vet. Pathol. **43**(6): 863–880.
1221
- 1222 NIOSH (National Institute for Occupational Safety and Health). 1993. Registry of toxic effects of chemical substances.
1223 6th ed. Rockville, Maryland.
1224
- 1225 Okonski, A.I., MacDonald, D.B., Potter, K., and Bonnell, M. 2021. Deriving predicted no-effect concentrations
1226 (PNECs) using a novel assessment factor method. Hum. Ecol. Risk Assess. **27**(6): 1613–1635.
1227
- 1228 Randhawa, N., Gulland, F., Ylitalo, G.M., DeLong, R., and Mazet, J.A. 2015. Sentinel California sea lions provide
1229 insight into legacy organochlorine exposure trends and their association with cancer and infectious disease.
1230 One Health **1**: 37–43.
1231
- 1232 Rao, A., Sanchez, M., Sutherland, D., and P. Lilley. 2019. Water Quality Assessment and Updated Objectives for
1233 Burrard Inlet: Introduction. Prepared for Tsleil-Waututh Nation and the Province of B.C.
- 1234 Raverty, S., St. Leger, J.S., Noren, D.P., Burek Huntington, K.B., Rotstein, D.S., Gulland, F.M.D., Ford, J.K.B.,
1235 Hanson, M., Lambourn, D.M., Huggins, J., Delaney, M.A., Spaven, L., Rowles, T., Barre, L., Cottrell, P.,
1236 Ellis, G., Goldstein, T., Terio, K., Duffield, D., Rice, J., and Gaydos, J.K. 2020. Pathology findings and
1237 correlation with body condition index in stranded killer whales (*Orcinus orca*) in the Northeastern Pacific
1238 and Hawaii from 2004 to 2013. PLoS One **15**: e0242505.
1239
- 1240 Ross, P.S. 2000. Marine mammals as sentinels in ecological risk assessment. Hum. Ecol. Risk Assess. **6**: 29–46.
1241
- 1242 Ross, P.S., and Birnbaum, L.S. 2003. Integrated human and ecological risk assessment: A case study of persistent
1243 organic pollutants (POPs) in humans and wildlife. Hum. Ecol. Risk Assess. **9**(1): 303–324.
1244
- 1245 Ross, P., De Swart, R., Addison, R., Van Loveren, H., Vos, J., and Osterhaus, A. 1996. Contaminant-induced
1246 immunotoxicity in harbour seals: wildlife at risk? Toxicology **112**: 157–169. doi: 10.1016/0300-
1247 483x(96)03396-3
1248
- 1249 Sample, B., and Arenal, C. 1999. Allometric models for interspecies extrapolation of wildlife toxicity data. Bull.
1250 Environ. Contam. Toxicol. **62**: 653–663. doi: 10.1007/s001289900924
1251
- 1252 Stedeford, T., Hsu, C.H., Zhao, Q.J., Dourson, M.L., and Banasik, M. 2007. The application of non-default uncertainty
1253 factors in the US EPA's Integrated Risk Information System (IRIS). Part I: UF (L), UF (S), and "other

1254 uncertainty factors". J. Environ. Sci. Health. Part C, Environmental Carcinogenesis & Ecotoxicology
1255 Reviews, **25**(3): 245-279. doi: 10.1080/10590500701569430
1256
1257 US EPA (Environmental Protection Agency). 2000. Methodology for deriving ambient water quality criteria for the
1258 protection of human health (2000). Washington, DC. Final Report October 2000. EPA-822-B-00-004.
1259
1260 US EPA (Environmental Protection Agency). 2002. A review of the reference dose and reference concentration
1261 processes. Prepared for the Risk Assessment Forum. Washington, DC. Final Report December 2002.
1262 EPA/630/P-02/002F.
1263
1264 US EPA (Environmental Protection Agency). 2014. Guidance for applying quantitative data to develop data-derived
1265 extrapolation factors for interspecies and intraspecies extrapolation. Risk Assessment Forum, Office of the
1266 Science Advisor, Washington, DC. EPA/100/R-14/002.
1267
1268 US EPA (Environmental Protection Agency). n.d. Regional screening levels (RSLs).
1269 <https://www.epa.gov/risk/regional-screening-levels-rsls>.

DRAFT FOR REVIEW ONLY – DO NOT CITE OR COPY

1270 APPENDICES

1271

1272 Appendix A: Compilation and Evaluation of Toxicity Data

1273

1274 Given the sparsity of data for marine mammals and the desire to protect highly vulnerable
1275 individuals, endpoints are not restricted to the survival, reproduction and growth endpoints
1276 traditionally used to develop guidelines. All endpoints are accepted if there is scientific evidence
1277 available that links the endpoint to an adverse outcome in a mammalian species. Adverse effects
1278 could include:

1279

- 1280 • Systemic toxicity such as to the liver, kidney or general system
- 1281 • Neurotoxicity evidenced by behavioural differences or brain pathology
- 1282 • Reproductive toxicity that results in effects on fertility or the ability to reproduce
- 1283 • Endocrine toxicity that affects organs such as the thyroid gland or circulating
1284 concentrations of hormones such as estrogen, testosterone or thyroid hormones
- 1285 • Developmental toxicity, including effects on the developing fetus or maternal systemic
1286 effects that interfere with development
- 1287 • Immunotoxicity that affects immune system organs such as the spleen and thymus, or
1288 general immune function disorders

1289

1290 Acceptable endpoints include omics endpoints if they are anchored through a plausible AOP. An
1291 AOP consists of three main components: a molecular initiating event where the substance interacts
1292 with the biochemistry of the organism; one or more key events where the alteration in the
1293 biochemistry leads to an alteration in cell, tissue or organ functioning; and an identified adverse
1294 outcome that has the potential to impair the growth, reproduction and survival of an organism.
1295 Using AOPs is an emerging approach, and most AOPs are still under development. It is not
1296 necessary to firmly establish each of the key events in the AOP but rather to note that the scientific
1297 literature has established a high likelihood that the pathway occurs.

1298

1299 All studies used in the development of a guideline must be evaluated to ensure that acceptable
1300 laboratory, field or computational practices were used in the design and execution of the study.
1301 The exception is studies previously screened and included in the ATSDR database or evaluated by
1302 Health Canada or the US EPA, which can automatically be included with no additional screening.
1303 Contamination, sampling procedure, sample preservation, storage, pre-concentration and filtration
1304 may all be sources of errors, rendering the task of achieving precision and accuracy complex. A
1305 thorough investigation of the data (technique and reliability) must be performed before considering
1306 the measured concentrations as acceptable values for a guideline derivation (CCME 2007).

1307

1308 While the evaluation of toxicological data should follow a basic format with certain requirements,
1309 scientific judgement is often required for the classification of studies. It is not mandatory for
1310 toxicity studies to follow standard design protocols; however, the data must be appropriate with
1311 respect to the substance in question. Nonstandard testing procedures can yield usable results and
1312 should be evaluated on a case-by-case basis for inclusion in the data set. Since standard protocols
1313 for toxicity testing may become outdated, and are not always available or followed, a great deal of
1314 variability exists in the quality of published data.

1315 To ensure a consistent scientific evaluation for each substance, the following questions should be
1316 used to evaluate the quality of each study for the experimental approaches listed here.

1317
1318 All studies (criteria taken directly from US EPA 2002):
1319

- 1320 • What was the purpose of the study and is there a clearly delineated hypothesis?
- 1321 • Is there sufficient description of the protocol, statistical analysis and results to make an
1322 evaluation?
- 1323 • Were the appropriate endpoints assessed in the study? Were the techniques used for the
1324 assessment scientifically sound?
- 1325 • Were appropriate statistical techniques applied for each endpoint? Was the power of the
1326 study adequate to detect effects?
- 1327 • Did the study establish dose-response relationships (e.g., lowest observed adverse effect
1328 level [LOAEL], effect concentration affecting 10% of the test organisms [EC10])?
- 1329 • Is the shape of the dose-response curve consistent with the known toxicokinetics of the test
1330 compound?

1331
1332 *In vivo* laboratory dose-response studies from any mammal (criteria taken directly from US EPA
1333 2002):
1334

- 1335 • Was the study sufficiently documented (e.g., conducted in accordance with good laboratory
1336 practices)?
- 1337 • Were appropriate analytical techniques used to measure the stability, homogeneity and
1338 actual level of the test substance in the study (in the water, feed, air, etc.)?
- 1339 • Were the dose levels appropriate? What was the basis for choosing the dose levels?
- 1340 • Was an appropriate method used to assign the animals to the dose groups?
- 1341 • Was an appropriate route and matrix of exposure employed?
- 1342 • Was the duration of exposure adequate for the study design?
- 1343 • Were possible alterations in metabolism considered at the higher exposure levels?
- 1344 • Does the study demonstrate a clear dose-response relationship? Studies with limited
1345 treatment levels may be considered if other toxicological studies support the effect level.
- 1346 • Does the study report dosage rates (in $\text{mg}\cdot\text{kg}^{-1}\cdot\text{d}^{-1}$), exposure duration, formulation and the
1347 administration method used in the study? Dosage rates that have been estimated are
1348 acceptable, but measured dosage rates are preferred.
- 1349 • Was the substance administered in the test via the oral route (i.e., in food, in water or by
1350 gavage)? Dietary exposure studies are preferred. Tests using other administration methods
1351 (i.e., dermal, respiratory, intravenous, intramuscular, subcutaneous or intra-peritoneal)
1352 should not be used unless sufficient supportive information on the pharmacokinetics
1353 (absorption, distribution, metabolism and excretion) of the substance was available and the
1354 dosage was measured.

1355

1356 *In vitro* studies (criteria from Emmerich and Harris 2019):

1357

1358 • Does the methodology include all minimum information requirements of the experiment
1359 type? If none exist, is information given on buffer (e.g., cell culture medium), lysis
1360 conditions, sample preparation, and handling and incubation times?

1361 • Are the sources of all materials (e.g., cells, antibodies, enzymes, proteins, nucleic acids,
1362 chemicals) clearly listed, including vendor, catalogue number and lot number?

1363 • For non-commercially-sourced materials, were the necessary quality control analyses
1364 conducted to validate their identity, purity, and biological activity?

1365 • Was the source of recombinant proteins reported? This includes the sequence, expression
1366 system, purification and analysis for purity and bioactivity.

1367 • Were inhibitors and compounds specifically screened to identify off-target effects?

1368 • Were the methods for purifying and preparing cell lines described?

1369 • Were antibodies screened for specificity and cross-reactivity?

1370 • Did the study design include adequate replication and randomization?

1371 • Was the statistical analysis clearly described and were the corresponding sample size and
1372 error bars reported?

1373

1374 *In silico* studies (criteria from Myatt *et al.* 2018):

1375

1376 • Were all steps and methodologies transparently documented, including the exact software
1377 used? (Though not essential, it is best practice for researchers to supply the data and code
1378 so the experiment can be replicated.)

1379 • Was the training data set of high quality?

1380 • Did the model have a high prediction reliability?

1381 • Was the selection of structural descriptors biologically meaningful?

1382 • Is there support in the literature for the relationships between structural descriptors and
1383 toxicological effect?

1384 • Were the results explained in relation to current toxicological knowledge?

1385 • Were weaknesses in the approach and necessary steps for further validation clearly
1386 described?

1387

1388
1389
1390
1391

Appendix B: Individual-based Model Input Values and Rate of Food Intake to Body Weight Estimates

Table B1. Individual-based Model Parameters and Input Values for Orca and Beluga

Time parameters	Orca	Beluga
Years model runs after weaning	68	68
First possible year of pregnancy	15	9
Julian day of copulation	35	35
Julian day of birth	545	455
Julian day of weaning	1278	1,278
Number of days between standard output reports	60	120
Percentage of weaning time calf is in food transition	20	20
Stage-specific food intake multipliers		
Food multiplier for juvenile	1.3	1.3
Food multiplier for adult	1.3	1.3
Food multiplier during pregnancy	1.3	1.3
Food multiplier during lactating	1.3	1.3
Body compartment parameters		
Maximum blubber proportion of body weight	0.29	0.4
Minimum blubber proportion of body weight	0.28	0.4
Fetal blubber proportion of body weight	0.17	0.17
Lipid proportion of blubber, female	0.4	0.8
Lipid proportion of core	0.05	0.05
Ratio of support to fetal mass at term	1	1.0
Nonpregnant base uterus weight	0.05	0.05
Ratio of placental to support mass	0.25	0.25
Female orca growth parameters		
Maximum length parameter	564	365
Gompertz B-value length	0.885	0.8805
Gompertz K-value length	0.27000	0.00044
Maximum weight parameter	2703	680
Gompertz B-value weight	2.7	2.572
Gompertz K-value weight	0.00046	0.00044
Male orca growth parameters		
Maximum length parameter	683	416
Gompertz B-value length	1.08	0.987
Gompertz K-value length	0.1752	0.000375
Maximum weight parameter	5015	995
Gompertz B-value weight	3.3	2.895
Gompertz K-value weight	0.00046	0.000375
Lipid proportion of blubber, male	0.4	0.8

OR COPY

Stage-specific metabolic rate multipliers		
1.5 to 3.0 x BMR for neonate (lact)	4	4
1.5 to 3.0 x BMR for first year	4	4
1.5 to 3.0 x BMR for juvenile	4	4
1.5 to 3.0 x BMR for adult (non-reproductive or male)	4	4
1.5 to 3.0 x BMR for adult (pregnant)	4	4
1.5 to 3.0 x BMR for adult (lactating)	4	4
Energetics parameters		
kcal·kg ⁻¹ food	1,800	1,778
Digestibility of food	0.82	0.82
kcal required to add 1 kg of core mass	9,100	9,100
kcal required to add 1 kg of blubber mass	9,100	9,100
kcal required to add 1 kg of fetus or uterus mass	9,100	9,100
kcal·kg ⁻¹ blubber energy density	8,500	8,500
Energy efficiency of blubber mobilization	0.9	0.9
kcal·kg ⁻¹ of milk energy density	3,325	3,000
Lipid proportion in milk	0.3	0.27
Digestibility of milk	0.9	0.9
Energy efficiency in milk production	0.9	0.9
Contaminant kinetics terms		
log K _{ow} for chemical	6.8	6.8
TOX assimilation from food	0.724	0.724
TOX assimilation from milk	0.9	0.9
Blubber-milk TOX partition coefficient	0.490	0.490
Adult TOX whole-body clearance rate (per day)	0.00009	0.000055
Neonate TOX whole-body clearance rate (per day)	0.00009	0.000055
Placenta effect on mother-fetus partition	0.556	0.556
Diet energy content calculation kcal·kg⁻¹ wet weight		
Protein % of wet weight (5,600 kcal·kg ⁻¹)	20	20
Lipid % of wet weight (9,400 kcal·kg ⁻¹)	8.0	7.0
Pregnant in years	15, 20, 25, 30, 35, 40	10, 13, 16, 19, 22, 25, 28, 31, 34

Notes

The parameters and input values for orca and beluga in Table B1 are taken from Hickie *et al.* (2007). Tox assimilation from food equation is given by McLachlan (1994); blubber-milk tox partition coefficient equation is given by Cadieux *et al.* (2016); and placenta effect on mother-fetus partition equation is given by Desforges *et al.* (2012).

1392
1393
1394
1395
1396
1397
1398
1399
1400
1401
1402

OR COPY

Table B2. Individual-based Model Parameters and Input Values for Ringed Seal

Time parameters	Ringed seal
Years model runs after weaning	25
First possible year of pregnancy	7
Julian day of birth (April 1)	90
Julian day of weaning and copulation	130
Julian day of implantation (August 4)	215
Julian day of moult start	180
Julian day of moult, end	210
Number of days between standard output reports	30
Stage-specific food intake multipliers	
Food multiplier for juvenile	1.3
Food multiplier for adult	1.3
Food multiplier during moult	0.7
Food multiplier during lactating	0.6
Body compartment parameters	
Maximum blubber proportion of body weight	0.4
Minimum blubber proportion of body weight	0.25
Fetal blubber proportion of body weight	0.055
Lipid proportion of blubber	0.8
Lipid proportion of core	0.05
Ratio of support to fetal mass at term	1.0
Nonpregnant base uterus weight	0.05
Ratio of placental to support mass	0.25
Female growth parameters	
Maximum length parameter (cm)	126.85
Gompertz B value	0.3377
Gompertz K value	0.00032
Length (cm) to weight (kg) slope	3.2544
Length (cm) to weight (kg) constant	5.0596
Male growth parameters	
Maximum length parameter (cm)	131.21
Gompertz B value	0.400
Gompertz K value	0.0005
Length (cm) to weight (kg) slope	3.0685
Length (cm) to weight (kg) constant	4.693
Stage-specific metabolic rate multipliers	
1.5 to 4.0 x BMR for neonate (lactation)	1.0
1.5 to 4.0 x BMR for first year	4.0
1.5 to 4.0 x BMR for juvenile	4.0

CITE OR COPY

Stage-specific metabolic rate multipliers (Cont.)	
1.5 to 4.0 x BMR for adult (non-reproductive, male)	4.0
1.5 to 4.0 x BMR for adult (pregnant)	4.0
1.5 to 4.0 x BMR for adult (lactating)	4.0
Metabolic rate modifier for moulting	0.8
Energetics parameters	
kcal·kg ⁻¹ food	1,684
Digestibility of food	0.82
kcal required to add 1 kg core mass	9,100
kcal required to add 1 kg blubber mass	9,100
kcal required to add 1 kg fetus/uterus mass	9,100
kcal·kg ⁻¹ blubber energy density	8,500
Energy efficiency of blubber mobilization	0.9
kcal·kg ⁻¹ milk energy density	4,000
Lipid proportion in milk	0.38
Digestibility of milk	0.9
Energy efficiency in milk production	0.9
Contaminant kinetics terms	
Name of contaminant in this run	K _{ow} trial
log K _{ow} for chemical	6.8
TOX assimilation from food	0.724
TOX assimilation from milk	0.9
Blubber-milk TOX partition coefficient	0.490
Adult TOX whole-body clearance rate (per day)	0.000027
Neonate TOX whole-body clearance rate	0.000027
Placenta effect on mother-fetus partition	0.556
Diet energy content calculation	
kcal·kg⁻¹ wet weight	
Protein percentage of wet weight (5,600 kcal·kg ⁻¹)	20
Lipid percentage of wet weight (9,400 kcal·kg ⁻¹)	6.0
Pregnant in years	8, 9, 11, 13, 14, 15, 17, 19, 20, 22, 23

Note

The parameters and input values for ringed seal in Table B2 are taken from Hickie *et al.* (2005).

1404
1405
1406
1407
1408
1409
1410
1411
1412

1413 **Table B3. Rates of Food Intake to Body Weigh (Percentage of Body Weight per Day)**
 1414 **for Five Subgroups of Arctic Ringed Seals, Beluga Whales and Killer Whales**
 1415 **Estimated with the Individual-Based Bioaccumulation Models**

	Juveniles	Adult males 10 to 60 years	Adult females		
			Non-pregnant	Pregnant	Nursing
Arctic ringed seals	8.8 ± 1.2	7.6 ± 0.3	8.3 ± 0.5	8.5 ± 0.6	10.4 ± 1.8
Beluga whales	5.1 ± 0.7	3.5 ± 0.2	3.8 ± 0.1	4.2 ± 0.4	4.8 ± 0.3
Killer whales	3.5 ± 0.8	2.3 ± 0.1	2.7 ± 0.1	2.8 ± 0.1	3.3 ± 0.3

1416 **Notes**

1417 Juveniles are considered to be from ages 1.2 to 10 years for beluga and 1.0 to 15 years for killer whales. Differences between the
 1418 two species are primary due to differences in body mass.

DRAFT FOR REVIEW ONLY – DO NOT CITE OR COPY